Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/maintenance-therapy-for-patients-with-advanced-non-small-cell-lung-3mLGLv0nUA
References (37)
-
R. Gaafar, V. Surmont, G. Scagliotti, R. Klaveren, D. Papamichael, J. Welch, B. Hasan, V. Torri, J. Meerbeeck (2010)
A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03).Journal of Clinical Oncology, 28
-
F. Shepherd, J. Pereira, T. Ciuleanu, E. Tan, V. Hirsh, S. Thongprasert, D. Campos, Savitree Maoleekoonpiroj, M. Smylie, R. Martins, M. Kooten, M. Dediu, B. Findlay, D. Tu, D. Johnston, A. Bezjak, G. Clark, P. Santabarbara, L. Seymour (2005)
Erlotinib in previously treated non-small-cell lung cancer.The New England journal of medicine, 353 2
-
C. Belani, D. Waterhouse, H. Ghazal, S. Ramalingam, R. Bordoni, R. Greenberg, R. Levine, J. Waples, Yixing Jiang, G. Reznikoff (2010)
Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC).Journal of Clinical Oncology, 28
-
K. Takeda, T. Hida, Tosiya Sato, M. Ando, T. Seto, M. Satouchi, Y. Ichinose, N. Katakami, N. Yamamoto, S. Kudoh, J. Sasaki, K. Matsui, K. Takayama, T. Kashii, Y. Iwamoto, T. Sawa, I. Okamoto, T. Kurata, K. Nakagawa, M. Fukuoka (2010)
Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 5
-
T. Ciuleanu, T. Brodowicz, C. Zielinski, J. Kim, M. Krzakowski, E. Laack, Yi-long Wu, I. Bover, StephenD. Begbie, V. Tzekova, B. Čučević, J. Pereira, S. Yang, J. Madhavan, K. Sugarman, P. Peterson, W. John, K. Krejcy, C. Belani (2009)
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 studyThe Lancet, 374
-
A. Sandler, R. Gray, M. Perry, J. Brahmer, J. Schiller, A. Dowlati, R. Lilenbaum, David Johnson (2006)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.The New England journal of medicine, 355 24
-
Joon-Oh Park, Sang-We Kim, J. Ahn, C. Suh, Jung Lee, J. Jang, E. Cho, S. Yang, Jin-Hyuk Choi, D. Heo, S. Park, S. Shin, M. Ahn, J. Lee, Y. Yun, Jae-Won Lee, Keunchil Park (2007)
Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 33
-
M. Reck, J. Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, N. Moore, C. Manegold (2009)
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 8
-
F. Ciardiello, R. Caputo, R. Bianco, V. Damiano, G. Pomatico, S. Placido, A. Bianco, G. Tortora (2000)
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 5
-
J. Schiller, D. Harrington, C. Belani, C. Langer, A. Sandler, J. Krook, Junming Zhu, David Johnson (2002)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.The New England journal of medicine, 346 2
-
T. Lynch, T. Patel, L. Dreisbach, M. Mccleod, W. Heim, R. Hermann, E. Paschold, N. Iannotti, S. Dakhil, S. Gorton, V. Pautret, Martin Weber, D. Woytowitz (2010)
Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 6
-
A. Jemal, R. Siegel, Elizabeth Ward, Y. Hao, Jiaquan Xu, M. Thun (2009)
Cancer Statistics, 2009CA: A Cancer Journal for Clinicians, 59
-
F. Shepherd, J. Dancey, R. Ramlau, K. Mattson, R. Gralla, M. O'Rourke, N. Levitan, L. Gressot, M. Vincent, R. Burkes, Susan Coughlin, Yong Kim, J. Bérille (2000)
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 10
-
B. Coudert, T. Ciuleanu, Keunchil Park, Yi-Long Wu, G. Giaccone, Wolfram Brugger, P. Gopalakrishna, Federico Cappuzzo (2012)
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.Annals of oncology : official journal of the European Society for Medical Oncology, 23 2
-
D. Pfister, David Johnson, C. Azzoli, W. Sause, Thomas Smith, Sherman Baker, J. Olak, D. Stover, John Strawn, A. Turrisi, M. Somerfield (2004)
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 2
-
M. Pérol, C. Chouaid, B. Milleron, R. Gervais, F. Barlesi, V. Westeel, J. Crequit, H. Léna, A. Vergnenègre, D. Pérol (2010)
Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study.Journal of Clinical Oncology, 28
-
C. Plessen, B. Bergman, Olga Andresen, R. Bremnes, S. Sundstrøm, M. Gilleryd, RM Stephens, J. Vilsvik, U. Aasebø, S. Sörenson, S. Sörenson (2006)
Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancerBritish Journal of Cancer, 95
-
G. Scagliotti, N. Hanna, F. Fossella, K. Sugarman, J. Blatter, P. Peterson, L. Simms, F. Shepherd (2009)
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.The oncologist, 14 3
-
P. Fidias, S. Dakhil, A. Lyss, D. Loesch, D. Waterhouse, J. Bromund, Ruqin Chen, Maria Hristova-Kazmierski, J. Treat, C. Obasaju, M. Marciniak, J. Gill, J. Schiller (2009)
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 4
-
F Cappuzzo, T Ciuleanu, K Park, Y Wu, G Giaccone (2010)
Erlotinib maintenance therapy in patients with stable disease after first-line platinum-doublet chemotherapy for advanced NSCLCAnn Oncol, 21
-
C. Belani, T. Brodowicz, T. Ciuleanu, J. Kim, M. Krzakowski, E. Laack, Y. Wu, P. Peterson, K. Krejcy, C. Zielinski (2009)
Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
Goldie Jh, Coldman Aj (1979)
A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.Cancer treatment reports, 63
-
M. Socinski, M. Schell, A. Peterman, K. Bakri, Steven Yates, R. Gitten, P. Unger, Joanna Lee, Ji Lee, M. Tynan, M. Moore, M. Kies (2002)
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 5
-
Vincent Miller, P. O'Connor, C. Soh, F. Kabbinavar (2009)
A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
(1995)
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 311
-
V. Westeel, E. Quoix, D. Moro-Sibilot, M. Mercier, J. Breton, D. Debieuvre, P. Richard, M. Haller, B. Milleron, D. Herman, M. Level, F. Lebas, M. Puyraveau, A. Depierre (2005)
Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.Journal of the National Cancer Institute, 97 7
-
G. Scagliotti, P. Parikh, J. Pawel, B. Biesma, J. Vansteenkiste, C. Manegold, P. Serwatowski, U. Gatzemeier, R. Digumarti, M. Zukin, J. Lee, A. Mellemgaard, Keunchil Park, S. Patil, J. Rolski, T. Goksel, F. Marinis, L. Simms, K. Sugarman, D. Gandara (2008)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 21
-
T. Brodowicz, M. Krzakowski, M. Zwitter, V. Tzekova, R. Ramlau, N. Ghilezan, T. Ciuleanu, B. Čučević, K. Gyurkovits, E. Ulsperger, J. Jassem, M. Grgić, P. Saip, M. Szilasi, C. Wiltschke, M. Wagnerová, N. Oskina, V. Soldatenkova, C. Zielinski, M. Wenczl (2006)
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.Lung cancer, 52 2
-
N. Hanna, F. Shepherd, F. Fossella, J. Pereira, F. Marinis, J. Pawel, U. Gatzemeier, T. Tsao, M. Pless, T. Muller, H. Lim, C. Desch, K. Szondy, R. Gervais, Shaharyar, C. Manegold, S. Paul, P. Paoletti, L. Einhorn, P. Bunn (2004)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 9
-
F. Sirotnak, M. Zakowski, V. Miller, H. Scher, M. Kris (2000)
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 12
-
F. Cappuzzo, T. Ciuleanu, L. Stelmakh, S. Cicėnas, A. Szczesna, E. Juhász, E. Esteban, O. Molinier, W. Brugger, I. Melezínek, G. Klingelschmitt, B. Klughammer, G. Giaccone (2010)
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.The Lancet. Oncology, 11 6
-
R. Pirker, J. Pereira, A. Szczesna, J. Pawel, M. Krzakowski, R. Ramlau, I. Vynnychenko, Keunchil Park, Chih-Teng Yu, V. Ganul, J. Roh, E. Bajetta, K. O'Byrne, F. Marinis, W. Eberhardt, T. Goddemeier, M. Emig, U. Gatzemeier (2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialThe Lancet, 373
-
R. Gaafar, V. Surmont, G. Scagliotti, R. Klaveren, D. Papamichael, J. Welch, B. Hasan, V. Torri, J. Meerbeeck (2011)
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).European journal of cancer, 47 15
-
I. Smith, M. O'Brien, D. Talbot, M. Nicolson, J. Mansi, T. Hickish, A. Norton, S. Ashley (2001)
Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 5
-
Y. Soon, M. Stockler, L. Askie, M. Boyer (2009)
Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 20
-
G. Buccheri, D. Ferrigno, Antonio Curcio, F. Vola, A. Rosso (1989)
Continuation of chemotherapy versus supportive care alone in patients with inoperable non‐small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective studyCancer, 63
-
F. Kabbinavar, V. Miller, B. Johnson, P. O'Connor, C. Soh, Atlas Investigators (2010)
Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).Journal of Clinical Oncology, 28
- Publisher
- Springer Journals
- Copyright
- Copyright © 2011 by Springer
- Subject
- Medicine & Public Health; Oncology; Medicine/Public Health, general
- ISSN
- 1865-5041
- eISSN
- 1865-5076
- DOI
- 10.1007/s12254-011-0242-y
- Publisher site
- See Article on Publisher Site
Abstract
Most patients with non-small cell lung cancer (NSCLC) present with advanced, metastatic disease. Although treatment of these patients was recently improved with the discovery of EGFR and ALK targeting, molecular targeted drugs, most patients require chemotherapy. The outcome of patients with advanced NSCLC lacking EGFR or ALK mutations remains disappointing, with a median overall survival of 12–14 months. To improve survival and quality of life, the concept of maintenance therapy after first-line chemotherapy has gained interest, especially in the light of efficacious and better tolerable drugs and the results of recent clinical trials. However, the topic of maintenance therapy remains controversial and complex. Therefore, we give an overview on the current evidence and discuss our personal recommendations for clinical practice.
Journal
memo - Magazine of European Medical Oncology – Springer Journals
Published: Apr 21, 2011